Cutting Social Security Benefits Is OK With 54% of Senators
A proposal by Bernie Sanders to protect entitlement programs from spending cuts as part of the Senate's tax-reform bill was soundly defeated.
Why 2017 Was a Year to Remember for NVIDIA Corp.
Skyrocketing revenue and earnings propelled the GPU leader to superb share price gains.
Here's My Top Stock to Buy in December
The fourth quarter of every year is usually the strongest for ethanol producers. But there's another major catalyst (and several smaller ones) this year.
ABM earnings call for the period ending October 31, 2017.
Another analyst has assigned a sky-high value to the department store chain's portfolio.
Here's a look at the beastly new computer -- and why it will likely drive growth at Apple.
The $54.2 billion deal will have big implications for Disney's cable and studio properties, but let's not forget about what this could mean for Disneyland and Disney World.
Investors have waited all year for the company to beef up its top line with an acquisition. Maybe Kraft Heinz should temper this expectation in 2018.
One Wall Street firm takes aim at Valeant.
NDSN earnings call for the period ending October 31, 2017.
Third time's the charm?
New ad features from Apple are hurting the advertising retargeting leader. Here's what investors need to know.
Want a retirement free of money worries? Here's how to manage this feat.
Artificial intelligence is being applied to a wide variety of technical challenges, and this is just the latest way in which Google is applying AI to the area of healthcare.
With the company's business accelerating and acquisition of Numerex complete, now is a great time to buy shares of the Internet of Things pure play
After more than doubling in 2016, the silver miner's stock lost its luster this year.
Investors are hoping for a rebound following weak sales numbers in previous quarters.
Rumors circulate that the cancer test maker has sparked takeover interest.
A corporate restructuring is boosting hope that the company can overcome significant headwinds.
We all make mistakes, but it's on us to learn from them.
The tiny yet promising biopharma may be taken more seriously after today.
The company earned a bullish rating from Wall Street.
At least one analyst sees the stock going much higher.